2. Necrotizing Fasciitis (and Related Necrotizing Soft Tissue Infections)

Quick Recap

Infectious Diseases System, Protocol 2/6. Also covers myonecrosis/gas gangrene and ecthyma gangrenosum as related must-not-miss soft tissue diagnoses.

1. Definition & Epidemiology

A RARE skin/soft tissue infection (SSTI) involving the DEEP FASCIA — always requires surgical intervention plus broad-spectrum IV antimicrobials; there is no medical-management-alone pathway. Incidence varies widely by region (0.18-15.5 per 100,000) and appears to be increasing over time. Mortality 20-70% — among the deadliest common ICU infectious presentations, driven largely by delay to surgical source control.

Predominantly affects the LOWER EXTREMITIES, with predisposing conditions explaining this predilection: diabetes, venous return abnormalities/arterial insufficiency, IV drug use.

2. Microbiologic Classification

Type I (polymicrobial): both aerobic and anaerobic organisms together — the more common type overall.

Type II (classically monomicrobial): Streptococcus pyogenes classically, though S. aureus also falls into this category. Emerging/regional variants exist (e.g., monomicrobial Klebsiella pneumoniae necrotizing fasciitis increasingly reported in Taiwan) — the range of causative organisms is genuinely broad, reinforcing that surgical debridement with cultures, combined with broad-spectrum empiric antibiotics, is the correct FIRST-LINE approach regardless of the eventually identified organism, rather than trying to narrow empiric coverage based on a presumed pathogen at presentation.

3. Clinical Recognition — The Central Diagnostic Challenge

Physical examination is OFTEN UNRELIABLE — patients frequently have NORMAL-APPEARING overlying skin, and overt necrotic signs (crepitus) are seen in only ~30% of patients. This is precisely why a high index of suspicion, not reliance on classic exam findings, must drive the workup.

Classic teaching: "pain out of proportion to examination" — but an important caveat: superficial nerves can undergo necrosis, causing CUTANEOUS ANESTHESIA of the affected area — so pain may actually DECREASE or disappear as the infection progresses and destroys the nerves supplying that skin, which can be misread as clinical improvement rather than disease progression. Eliciting history may be difficult given illness severity/altered sensorium — maintain suspicion even with an incomplete history.

Characteristics associated with increased likelihood of necrotizing infection:

• Pain out of proportion to examination
• Bullae
• Systemic toxicity
• Serum sodium <135 mmol/L; WBC >15,400 cells/mm3 (these two lab values are specifically cited as red flags, though formal risk scores using them are "not widely used" clinically despite being described)
• Tenderness extending BEYOND the visible area of erythema
• Crepitus
• Cutaneous anesthesia
• Cellulitis REFRACTORY to antibiotic therapy — a simple cellulitis that is not responding as expected to appropriate antibiotics should prompt reconsideration of a necrotizing process

4. Imaging — A Genuine Trap: Do NOT Let Imaging Delay Surgery

Imaging findings CANNOT RULE OUT necrotizing fasciitis given unacceptably low sensitivity, and pursuing imaging may DELAY surgical intervention, which is independently associated with WORSE outcomes.

• Plain radiography: shows soft tissue gas in only 15-30% of necrotizing infections — a NEGATIVE plain film does essentially nothing to exclude the diagnosis
• CT and ultrasound: sometimes helpful ancillary studies for soft tissue gas/necrotic tissue, but not sensitive enough to rule out disease
• MRI has HIGH SENSITIVITY but LOW SPECIFICITY, and practically, logistical difficulties in obtaining MRI urgently limit its utility in critically ill patients — even when sensitive, it is often not the right test given time-criticality

If clinical suspicion is HIGH, imaging should NOT delay surgical exploration — this is the single most important operational principle in this entire protocol.

5. Bedside Diagnostic Maneuver — When Imaging/Biopsy Is Too Slow

Bedside incision under local anesthesia with DIGITAL EXAMINATION of the tissue planes: facile (easy) separation of subcutaneous tissue from the fascia, with minimal resistance, is PATHOGNOMONIC for necrotizing soft tissue infection — a rapid, low-tech, high-value diagnostic maneuver that can be performed at the bedside without waiting for imaging or formal OR access, useful specifically to confirm the diagnosis and expedite definitive surgical debridement.

Biopsy with frozen section has been recommended for definitive diagnosis in equivocal cases, though this carries significant logistical difficulty when needed urgently — a less practical option than the bedside incision technique in most acute ICU scenarios.

6. Immediate Stabilization (ABCDE)

Circulation: treat as evolving septic shock if hemodynamically unstable — apply full Septic Shock protocol principles (fluid resuscitation, blood cultures before antibiotics, early vasopressors as needed).

The single most important intervention is TIME TO SURGICAL DEBRIDEMENT — every other stabilization measure runs in parallel with, not instead of, urgent surgical consultation.

Checklist:

7. Empiric Antibiotic Therapy

Broad-spectrum coverage against gram-positive cocci, gram-negative bacilli, AND anaerobes is mandatory for suspected necrotizing infection — do not narrow empirically based on a presumed single organism given the genuine microbiologic diversity (Section 2).

For confirmed MONOMICROBIAL infection due to S. pyogenes or Clostridia specifically: PENICILLIN PLUS CLINDAMYCIN is definitive therapy — clindamycin's value here is NOT primarily its antibacterial activity, but its ability to SUPPRESS BACTERIAL TOXIN PRODUCTION (inhibits protein synthesis, reducing exotoxin output that drives much of the systemic toxicity in streptococcal/clostridial necrotizing infections) — linezolid can serve the same toxin-suppression role in selected patients as an alternative.

MRSA coverage: given MRSA accounts for a majority (59% in one multi-center series) of SSTIs presenting to EDs, it is generally appropriate to include anti-MRSA coverage empirically — vancomycin traditionally, with linezolid, daptomycin, or ceftaroline as alternatives in critically ill patients. Negative MRSA nares swab has high negative predictive value for SSTIs generally, but this has NOT been specifically studied for necrotizing SSTIs — do not use a negative nares swab alone to discontinue empiric anti-MRSA therapy in a confirmed/suspected necrotizing infection.

8. Duration of Therapy

No clinical trials are available to guide duration given the disease's rarity, microbiologic heterogeneity, and severity — expert-opinion-based guidance suggests continuing therapy directed against the cultured organism(s) for at least 48-72 HOURS AFTER the patient is clinically stable and requires NO FURTHER operative interventions — duration is trajectory-driven (clinical stability + no further debridement needed) rather than a fixed calendar course.

9. Myositis / Pyomyositis / Gas Gangrene — Related, Distinguishable Entities

Myonecrosis (associated with GAS GANGRENE and clostridial infections) vs pyomyositis (almost universally S. aureus) — this distinction is CLINICALLY VITAL:

• Myonecrosis REQUIRES IMMEDIATE OPERATIVE DEBRIDEMENT, same urgency as necrotizing fasciitis
• Pyomyositis may be amenable to ANTIBIOTICS AND PERCUTANEOUS DRAINAGE — a meaningfully LESS aggressive pathway than myonecrosis, making correct differentiation clinically important rather than academic

Pyomyositis presentation: localized pain in a SINGLE muscle group with fever. MRI is the preferred imaging modality; bedside ultrasound is a useful rapid alternative.

Gas gangrene/myonecrosis organism-specific associations:

• Clostridium perfringens: classically traumatic injuries
• C. septicum: neutropenic patients or those with GI malignancy/abnormalities — a necrotizing soft tissue infection in a neutropenic or GI-malignancy patient should specifically raise C. septicum suspicion
• C. sordellii: childbirth and "home"/unsafe abortions — can cause a TOXIC-SHOCK-LIKE SYNDROME, particularly with recent parturition or abortion — a distinct, must-not-miss presentation in postpartum/post-abortion patients with unexplained shock
• C. perfringens, C. novyi, C. sordellii: associated with "skin-popping" (subcutaneous/intramuscular injection) drug use

10. Ecthyma Gangrenosum — A Related Cutaneous Vasculitis

Classically associated with Pseudomonas aeruginosa SEPTICEMIA, though many other pathogens implicated (other gram-negative bacilli, S. aureus, S. pyogenes, fungi, molds, atypical mycobacteria, viruses). Mechanism: invasion of medial and adventitial blood vessel walls by the causative organism (a vasculitic/vasculopathic process, distinct from the fascial-plane spread of necrotizing fasciitis).

Presentation: starts as painless erythematous nodules, evolves into painful necrotic ulcers with eschar, predominantly between the umbilicus and knees.

Management: broad-spectrum antimicrobial therapy including an agent with ANTIPSEUDOMONAL activity, given the classic (though not exclusive) Pseudomonas association.

11. Organ Support

Fluid resuscitation and vasopressor support per Septic Shock protocol principles if unstable; broad-spectrum antibiotics; standard ICU supportive care through the surgical debridement course (often requiring multiple staged debridements); nutrition support given the high catabolic burden of extensive soft tissue infection/debridement.

12. Consultation Matrix

13. Monitoring Framework

Serial wound/debridement site assessment (often requiring repeat staged debridement), hemodynamic monitoring, serial labs (WBC, lactate, renal function), watch for evolving/worsening septic shock, monitor for toxin-mediated complications (toxic shock physiology) especially with streptococcal/clostridial disease.

14. Complications

Septic shock, multi-organ failure, limb loss (amputation may be required for source control), toxic shock syndrome (streptococcal/clostridial toxin-mediated), death (20-70% mortality). Prevention: rapid recognition despite unreliable exam findings, avoiding imaging-related delay to surgery, prompt broad-spectrum antibiotics with toxin-suppressing agents (clindamycin/linezolid) for confirmed strep/clostridial disease. Rescue: repeat staged surgical debridement, escalating antimicrobial coverage per culture data, standard septic shock rescue therapies.

15. Escalation & De-escalation

Escalate: any suspicion of necrotizing infection -> immediate surgical consultation without waiting for imaging confirmation; hemodynamic instability -> full septic shock management.

De-escalate: source controlled (debridement complete, no further operative need), clinically stable for >=48-72h -> narrow antibiotics to culture-directed therapy, discontinue empiric broad coverage.

16. ICU Discharge Criteria

Source control achieved (no further debridement needed), hemodynamically stable off vasopressors, antibiotics narrowed and on a defined course (48-72h post-stability minimum), wound care plan established, nutrition support in place given catabolic burden.

17. Documentation & Medicolegal Checklist

18. Key Guidelines

Burnham JP, Kirby JP, Kollef MH. Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review. Intensive Care Med. 2016;42(12):1899-1911 — primary contemporary reference.

19. Controversies

Formal necrotizing-infection risk scores using laboratory values (CRP, hemoglobin, sodium, creatinine, glucose, WBC) exist but are "not widely used" in practice — clinical gestalt and the bedside incision technique remain more operationally relevant than calculated scores in most acute settings. MRI's high sensitivity is counterbalanced by low specificity and logistical impracticality in critically ill patients, leaving genuine ambiguity about its role when a diagnosis remains unclear but the patient is too unstable for prolonged imaging. Duration of antibiotic therapy is entirely expert-opinion-based given the absence of trial data, reflecting real uncertainty rather than a settled standard.

20. References

1. Sarkaria M, Warren DK. Cellulitis/Fasciitis/Myositis. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 40).
2. Burnham JP, Kirby JP, Kollef MH. Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review. Intensive Care Med. 2016;42(12):1899-1911.
3. Cheng NC, Yu YC, Tai HC, et al. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis. 2012;55(7):930-939.
4. Aldape MJ, Bryant AE, Stevens DL. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis. 2006;43(11):1436-1446.
5. Cohen AL, Bhatnagar J, Reagan S, et al. Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet Gynecol. 2007;110(5):1027-1033.
6. Das DK, Baker MG, Venugopal K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study 1990-2006. J Infect. 2011;63(6):429-433.

See also: Sepsis/Septic Shock (Infectious Diseases System) for the shared hemodynamic management framework this protocol builds on.